One-year Longitudinal Follow-up of Serologic Responses to Vaccination with 7-Valent Pneumococcal Conjugate Vaccine among HIV-infected Adult Patients
Date Issued
2010
Date
2010
Author(s)
Lu, Ching-Lan
Abstract
Clinical studies have shown that vaccination with pneumococcal conjugate vaccine (PCV) decreases incidence of invasive pneumococcal diseases among HIV-infected children and adults. However, longitudinal follow-up of serologic responses to conjugated pneumococcal vaccination are rarely performed among HIV-infected adult patients receiving combination antiretroviral therapy (CART).
From October 2008 to April 2009, 159 HIV-infected adult patients were enrolled who had never received pneumococcal vaccine before, were not taking immunosuppressives, or had no active opportunistic illnesses. Eighty patients received two doses of 7-valent PCV given one month apart and 79 received one dose. Anticapsular antibody responses against 4 serotypes were examined (6B, 14, 19F, and 23F) at the 3rd, 6th, 9th, and 12th month following vaccination with the use of ELISA after absorption with 10 μg/ml cell-wall polysaccharide and 30 μg/ml 22F polysaccharide. Significant antibody responses were defined as 2-fold or greater increase of antibody level following vaccination compared to baseline.
Antibody response rates following vaccination varied with the 4 serotypes examined during follow-up. At 6th month, the rate was highest for serotype 23F (1-dose vs. 2-dose, 60.0% vs. 61.8%, P=0.75), followed by 14 (58.2% vs. 63.6%, P=0.47), 19F (36.4% vs. 49.1%, P=0.15), and 6B (34.5% vs. 40.0%, P=0.50). At 12th month, the 1-dose vs. 2-dose response rate for serotype 23F. 14, 19F, and 6B was 45.5% vs. 56.4% (P=0.25), 52.7% vs. 52.7% (P=0.99), 29.1 vs. 40.0 (P=0.23), and 23.6% vs. 30.9% (P=0.39), respectively. No significant differences of serotype-specific IgG concentrations for each serotype at the 4 time points were observed between patients receiving 1 dose and those receiving 2 doses of PCV except for serotype 6B at third month. Higher nadir CD4 count, heterosexual patients, and hepatitis B carrier were more likely to mount antibody responses to all 4 pneumococcal serotypes tested. Patients who received 2 doses of vaccine had a higher response rate at sixth month compared to patients who received 1 dose.
In this longitudinal follow-up study of 7-valent conjugated pneumococcal vaccination, the response rate to different serotypes one year after PCV vaccination ranged from 21.5% to 60.0% among HIV-infected patients. Patients who received 2 doses of PCV achieved similar serological responses against 4 serotypes to those who received 1 dose of PCV.
From October 2008 to April 2009, 159 HIV-infected adult patients were enrolled who had never received pneumococcal vaccine before, were not taking immunosuppressives, or had no active opportunistic illnesses. Eighty patients received two doses of 7-valent PCV given one month apart and 79 received one dose. Anticapsular antibody responses against 4 serotypes were examined (6B, 14, 19F, and 23F) at the 3rd, 6th, 9th, and 12th month following vaccination with the use of ELISA after absorption with 10 μg/ml cell-wall polysaccharide and 30 μg/ml 22F polysaccharide. Significant antibody responses were defined as 2-fold or greater increase of antibody level following vaccination compared to baseline.
Antibody response rates following vaccination varied with the 4 serotypes examined during follow-up. At 6th month, the rate was highest for serotype 23F (1-dose vs. 2-dose, 60.0% vs. 61.8%, P=0.75), followed by 14 (58.2% vs. 63.6%, P=0.47), 19F (36.4% vs. 49.1%, P=0.15), and 6B (34.5% vs. 40.0%, P=0.50). At 12th month, the 1-dose vs. 2-dose response rate for serotype 23F. 14, 19F, and 6B was 45.5% vs. 56.4% (P=0.25), 52.7% vs. 52.7% (P=0.99), 29.1 vs. 40.0 (P=0.23), and 23.6% vs. 30.9% (P=0.39), respectively. No significant differences of serotype-specific IgG concentrations for each serotype at the 4 time points were observed between patients receiving 1 dose and those receiving 2 doses of PCV except for serotype 6B at third month. Higher nadir CD4 count, heterosexual patients, and hepatitis B carrier were more likely to mount antibody responses to all 4 pneumococcal serotypes tested. Patients who received 2 doses of vaccine had a higher response rate at sixth month compared to patients who received 1 dose.
In this longitudinal follow-up study of 7-valent conjugated pneumococcal vaccination, the response rate to different serotypes one year after PCV vaccination ranged from 21.5% to 60.0% among HIV-infected patients. Patients who received 2 doses of PCV achieved similar serological responses against 4 serotypes to those who received 1 dose of PCV.
Subjects
human immunodeficiency virus
Streptococcus pneumoniae
invasive pneumococcal disease
pneumococcal vaccine
7-valent pneumococcal conjugate vaccine
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-99-P97421005-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):8a6e065f4c4012e8b19d5c07370f3ff1